Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

GEORGIAMUNE INC.

Home Clinical Trial Sponsors and OrganizationsGEORGIAMUNE INC.

GEORGIAMUNE INC.

942 Clopper Rd, Gaithersburg, Maryland, United States

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

3

100.0%

Trial Status Distribution

Completed

1

33.3%

Recruiting

2

66.7%

Clinical Trials

Trials sponsored by this organization (3)

The Purpose of the Study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Single-ascending and Multiple-ascending Doses of GIM-407

Sep 202448 participants

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

May 2024117 participants

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Dec 2023111 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals
News

Back to Organizations